$CLLS, $EDIT, and $CRSP: Biotech Trio Skyrockets with a Remarkable +13.25% Weekly Surge
Robots for this industry :
Day Trader, Popular Stocks: Price Action Trading Strategy (TA&FA) - 30-day Annualized Return +33%
Day Trader: High Volatility Stocks for Active Trading (TA&FA) - 30-day Annualized Return +16%
Biotechnology companies have been a hotspot in the stock market recently, showing remarkable performance with a notable 13.25% increase in the past week. This impressive upswing is mirrored by the positive outlook for several key tickers in this sector, including CLLS, EDIT, and CRSP. In this article, we will explore the recent developments in these biotechnology companies and highlight key indicators that suggest their continued growth.
Group of Tickers: CLLS, EDIT, CRSP
Positive Outlook with Volume Indicator Backing
The positive outlook for these biotechnology stocks is supported by the Volume Indicator, a metric that signifies strong investor interest and demand for these stocks. Tickeron, a renowned market analysis tool, is optimistic about this group and predicts a further increase of over 4.00% within the next month, with a 56% likelihood. Notably, the daily ratio of advancing to declining volumes within this group was 2.35 to 1, highlighting a strong buying sentiment among investors.
MA50MA10 Indicator Confirms Positive Trend
An important technical indicator, the MA50MA10, has confirmed the positive outlook for one of the tickers in this group. This indicator, with an average accuracy of 90%, suggests a favorable trend for this stock. It's a sign that these biotechnology companies have strong underlying market dynamics supporting their growth.
Market Capitalization Insights
The average market capitalization across this group of biotechnology stocks is approximately 1.6 billion USD. The market cap for individual tickers within the group varies, with CRSP holding the highest valuation at 4 billion USD, while CLLS is the lowest-valued company at 159.1 million USD. These varying market caps reflect the diversity within the biotechnology sector.
High and Low Price Movements
Recent price movements for these stocks have been quite dynamic. On average, these stocks exhibited a weekly price growth of 78.2%, a monthly growth of 41.87%, and a quarterly growth of 0.83%. Notably, CLLS saw the highest weekly price growth at 170.88%, while EDIT experienced the most significant decline at 31.28%.
Key Stock Movements
CRSP's Volatile Week: CRISPR Therapeutics AG (CRSP) experienced a rollercoaster week. On 11/3/23, the stock witnessed a substantial gain of 18.08%, positioning it as a top weekly gainer. However, on 8/3/23, just a day later, CRSP declined by -7.45%, marking it as a top loser for the week. These rapid fluctuations suggest the need for vigilant monitoring of CRSP.
CLLS's Sharp Downturn: Cellectis SA (CLLS) encountered a tough week on 8/3/23, as it emerged as a top weekly loser among penny stocks with a significant drop of -16.52%. Investors should closely analyze the reasons behind this decline and consider the long-term prospects for CLLS.
Volume Surge: Volume has played a crucial role in the recent movements of these stocks. The average weekly volume growth for the group was an astounding 1270.43%, and the monthly and quarterly volume growth were 1064.05% and 1045.67%, respectively. This surge in volume indicates heightened market activity and interest in biotechnology stocks.
Key Technical Indicators for Individual Stocks
-
CLLS's Aroon Indicator: CLLS's Aroon Indicator entered a downward trend on October 31, 2023. This indicator suggests a potential strong downward move for the stock, with historical data indicating an 85% probability of a downward trend. Current price: $2.52. Support and resistance levels: $2.07 and $3.06, respectively. Recent trends show substantial uptrend growth during October and the week of 10/30/23 - 11/06/23.
-
EDIT's MACD Histogram: The Moving Average Convergence Divergence (MACD) for EDIT turned positive on October 25, 2023, indicating a 79% probability of continued upward momentum. Current price: $8.52. Support and resistance levels: $8.21 and $11.68, respectively. Recent trends show uptrend growth during October and the week of 10/30/23 - 11/06/23.
-
CRSP's RSI Oscillator: The RSI Oscillator for CRSP moved out of oversold territory on October 23, 2023, with a 90% probability of an upward move. Current price: $56.49. Resistance and support levels: $42.40 and $61.15, respectively. Recent trends show a downtrend during October and the week of 10/23/23 - 10/30/23.
In summary, the biotechnology sector, particularly represented by CLLS, EDIT, and CRSP, has recently demonstrated significant growth. Positive technical indicators, substantial volume increases, and notable price movements contribute to the overall optimism in this sector.
Momentum Indicator for CLLS turns negative, indicating new downward trend
CLLS saw its Momentum Indicator move below the 0 level on June 12, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 98 similar instances where the indicator turned negative. In of the 98 cases, the stock moved further down in the following days. The odds of a decline are at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for CLLS turned negative on May 08, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .
CLLS moved below its 50-day moving average on June 06, 2025 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CLLS crossed bearishly below the 50-day moving average on June 10, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLLS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for CLLS entered a downward trend on June 11, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CLLS advanced for three days, in of 231 cases, the price rose further within the following month. The odds of a continued upward trend are .
CLLS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.148) is normal, around the industry mean (16.950). P/E Ratio (0.000) is within average values for comparable stocks, (59.602). CLLS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.336). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (2.726) is also within normal values, averaging (257.570).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CLLS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLLS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a genome engineering company of pre-engineered products for pharmaceutical industry, cell therapies, seed companies, and laboratory researchers
Industry Biotechnology
Advertisement